Long‐term (up to 18 years) effects on GH/IGF‐1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH‐secreting pituitary adenoma responsive to SSTaJean Christophe Maiza, Philippe Caron, F. Loubes-Lacroix et al.|Clinical Endocrinology|2007Cited by 121
Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearanceMaria Matta, Philippe Caron, Elisabeth Couture et al.|European Journal of Endocrinology|2008Cited by 105